09:11 EDT Adial Pharmaceuticals up 109% at $2.36 after disclosing results from AD04 trial
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADIL:
- Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder
- Adial Pharma’s Cybersecurity Challenge: Navigating the Risks of IT Dependence in Data Management
- Adial Pharmaceuticals Reports 2023 Fiscal Year Financial Results and Provides Business Update
- ADIL Upcoming Earnings Report: What to Expect?
- Biotech Alert: Searches spiking for these stocks today